284 related articles for article (PubMed ID: 30273605)
1. Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2019 May; 189(5):966-974. PubMed ID: 30273605
[TBL] [Abstract][Full Text] [Related]
2. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
3. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
4. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
5. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
6. Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Shee K; Muller KE; Marotti J; Miller TW; Wells WA; Tsongalis GJ
Am J Pathol; 2019 May; 189(5):956-965. PubMed ID: 30385093
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
8. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
9. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL
Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733
[TBL] [Abstract][Full Text] [Related]
10. Identification of microRNAs in Nipple Discharge as Potential Diagnostic Biomarkers for Breast Cancer.
Zhang K; Zhao S; Wang Q; Yang HS; Zhu J; Ma R
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S536-44. PubMed ID: 25976861
[TBL] [Abstract][Full Text] [Related]
11. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
12. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
Lee J; Kim HE; Song YS; Cho EY; Lee A
Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460
[TBL] [Abstract][Full Text] [Related]
13. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
14. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
15. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
Woo JW; Choi HY; Kim M; Chung YR; Park SY
Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
[TBL] [Abstract][Full Text] [Related]
16. ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
Liu Y; Pandey PR; Sharma S; Xing F; Wu K; Chittiboyina A; Wu SY; Tyagi A; Watabe K
Breast Cancer Res Treat; 2019 May; 175(1):77-90. PubMed ID: 30725231
[TBL] [Abstract][Full Text] [Related]
17. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
[TBL] [Abstract][Full Text] [Related]
18. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L
Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]